Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent progress in ankylosing spondylitis treatment.

Eric Toussirot1, Daniel Wendling

  • 1Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F-25030 Besançon, France. eric.toussirot@ufc-chu.univ-fcomte.fr

Expert Opinion on Pharmacotherapy
|January 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotype.

EULAR rheumatology open·2026
Same author

Diagnostic accuracy of <sup>18</sup>F-FDG PET-CT scores in distinguishing polymyalgia rheumatica from other inflammatory rheumatic diseases: a multicentre retrospective study (RHUMATEP).

European journal of nuclear medicine and molecular imaging·2026
Same author

Discrepancies in the assessment of axial spondyloarthritis between patients and rheumatologists: what does this mean?

Clinical rheumatology·2026
Same author

Late-onset psoriatic arthritis: A separate entity.

Joint bone spine·2026
Same author

Bacterial translocation and intestinal permeability in early axial spondyloarthritis association with 5-year outcomes: insights from the DESIR cohort.

Rheumatology (Oxford, England)·2026
Same author

Clinical Images: A painful bipartite patella.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Ankylosing spondylitis (AS) management is evolving. New treatments like COX2 inhibitors, methotrexate, pamidronate, and anti-TNF agents show promise for severe cases refractory to NSAIDs and sulfasalazine.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Ankylosing spondylitis (AS) is a systemic inflammatory disease causing pain, stiffness, and functional loss.
  • Current treatments include exercise, NSAIDs, and second-line agents like sulfasalazine for refractory cases.
  • Severe AS necessitates novel therapeutic strategies due to inadequate disease control.

Purpose of the Study:

  • To review emerging therapeutic developments in ankylosing spondylitis management.
  • To assess the efficacy and potential of new treatment modalities for AS.

Main Methods:

  • Review of current literature on AS treatment.
  • Evaluation of new NSAIDs (COX2 selective agents).
  • Assessment of second-line treatments including methotrexate (MTX), pamidronate, and anti-TNFalpha agents.

Related Experiment Videos

Main Results:

  • Pamidronate demonstrated efficacy in NSAID-refractory AS patients.
  • Anti-TNFalpha agents (infliximab, etanercept) showed significant symptom improvement.
  • Controlled studies for MTX efficacy are lacking; further research is needed for anti-TNF agents' long-term effects.

Conclusions:

  • New treatments are emerging for severe and refractory ankylosing spondylitis.
  • Pamidronate and anti-TNFalpha agents represent promising therapeutic options.
  • Further long-term studies are essential to confirm the safety and effectiveness of these novel AS treatments.